Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3682B in chronic hepatitis C genotype 5 or 6 infection
2016-000620-26Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of uprifosbuvir, grazoprevir and ruzasvir in chronic hepatitis C (CHC) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects achieving SVR12. Started Jul 2016; status: terminated.
02
Drugs
uprifosbuvirgrazoprevirruzasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-000620-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000620-26.